.30
0.86%
+0.0026
(After Hours:
.30
+0.000100
+0.03%)
May-20-22 08:30AM | ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. |
May-16-22 07:30AM | ContraFect Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewswire Inc. |
Apr-18-22 07:30AM | ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID MeetingGlobeNewswire Inc. |
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
List of SPAC Stocks
List of EV Stocks and Related Stocks
Top 100 popular stocks on Robinhood
List of Marijuana Stocks
Cap:
|
Volume (24h):